William Ho

Company: IN8Bio
Job title: CEO
Seminars:
Donor Derived Gamma-Delta T Cells; Path Towards Sold Tumor Therapies 9:30 am
Reviewing gamma-delta T cells; nonrestrictive lymphocytes that are thought to be attractive for allogeneic therapies Outlining our INB-100 phase I program, which is the first to have delivered a large bolus of ex-vivo expanded and mismatched gamma-delta T cells into lymphodepleted leukemia patients Providing safety data to advance our donor derived INB-400 program into the…Read more
day: Day One